EcoR1 Capital’s Allogene Therapeutics ALLO Stock Holding History

EcoR1 Capital’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,488,200	Closed	-$14.2M	–	52
2023 Q3	$14.2M	Hold	4,488,200	–	–	0.48%	32
2023 Q2	$22.3M	Hold	4,488,200	–	–	0.55%	26
2023 Q1	$22.2M	Hold	4,488,200	–	–	0.71%	23
2022 Q4	$28.2M	Hold	4,488,200	–	–	0.86%	23
2022 Q3	$48.5M	Hold	4,488,200	–	–	1.43%	16
2022 Q2	$51.2M	Buy	+4,488,200	New	+$39.8M	1.77%	16

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital's ALLO Position: Q4 2023 in Review

EcoR1 Capital sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 4,488,200 shares — an estimated $14.2M sold.

EcoR1 Capital first reported a position in ALLO in Q2 2022 and held it in 6 quarters. The position peaked at $51.2M in Q2 2022. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

EcoR1 Capital reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
EcoR1 Capital sold 4,488,200 Allogene Therapeutics shares in Q4 2023, an estimated $14.2M.
EcoR1 Capital first reported a position in Allogene Therapeutics in Q2 2022 and held it in 6 quarters.
EcoR1 Capital's Allogene Therapeutics position peaked at $51.2M in Q2 2022.
170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on EcoR1 Capital's 13F filing for Q4 2023, filed 14 Feb 2024.